Central and peripheral glutamatergic biomarkers delineate heterogeneous clinical phenotypes in olanzapine-treated schizophrenia.

doi:10.1038/s41598-026-58148-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Central and peripheral glutamatergic biomarkers delineate heterogeneous clinical phenotypes in olanzapine-treated schizophrenia.

Scientific reports - 14 Jun 2026

Krzyściak Wirginia, Pilecki Maciej, Bystrowska Beata, Szwajca Marta, Śmierciak Natalia, Turek Aleksander, Karcz Paulina, Bryll Amira, Mazur Paulina, Gomółka Ewa, Popiela Tadeusz

Abstract excerpt

This study aimed to identify central and peripheral glutamatergic biomarkers underlying heterogeneous clinical phenotypes in olanzapine-treated patients with schizophrenia, with the goal of informing biomarker-guided personalized therapy. We conducted a cross-sectional observational study of 51 adults with schizophrenia receiving chronic olanzapine treatment (mean duration = 5.6 years), integrating clinical...

Read the complete abstract on PubMed

Topics

Adult
Female
Humans
Male
Middle Aged
Antipsychotic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Biomarkers

Cross-Sectional Studies

Glutamic Acid

Glutamine

Gyrus Cinguli

Magnetic Resonance Spectroscopy

Olanzapine

Phenotype

Schizophrenia

Serotonin

Source

Open in PubMed Open full text

Identifiers

PMID: 42289593
DOI: 10.1038/s41598-026-58148-z
PMCID: PMC13527110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Central and peripheral glutamatergic biomarkers delineate heterogeneous clinical phenotypes in olanzapine-treated schizophrenia.PMID 42289593Read ↗

Neurochemical Correlates and Heterogeneous Clinical Response to Olanzapine in Schizophrenia: A Multidimensional Analysis of Central and Peripheral BiomarkersSemantic proximity Read ↗

Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.Semantic proximity Read ↗

Variability and Magnitude of Brain Glutamate Levels in Schizophrenia: A Meta And Mega-AnalysisSemantic proximity Read ↗

Risk-Conferring Glutamatergic Genes and Brain Glutamate Plus Glutamine in SchizophreniaSemantic proximity Read ↗

Behavioural and molecular endophenotypes in psychotic disorders reveal heritable abnormalities in glutamatergic neurotransmission.Semantic proximity Read ↗

A multistage, dual voxel study of glutamate in the anterior cingulate cortex in schizophrenia supports a primary pyramidal dysfunction model of disorganizationSemantic proximity Read ↗

Proteomic Enrichment Analysis of Psychotic and Affective Disorders Reveals Common Signatures in Presynaptic Glutamatergic Signaling and Energy MetabolismSemantic proximity Read ↗

Distinct contributions of schizophrenia and neurotransmitter pathway genetic liability to neurocognition and antipsychotic efficacy in drug-naïve first-episode schizophrenia.Semantic proximity Read ↗

Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosisSemantic proximity Read ↗

Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis.Semantic proximity Read ↗

Post-mortem molecular profiling of three psychiatric disordersSemantic proximity Read ↗

Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.